Aesica Announces Partnership with Bradford University
News Jan 14, 2013
Aesica has announced a partnership with the Centre for Pharmaceutical Engineering Science at the University of Bradford, which will enable the team at Bradford to utilize the GMP capabilities and assets held at Aesica, while Aesica will benefit from the Centre’s extensive research facilities.
The partnership was formed following a presentation from Dr. Riddhi Shukla, business development manager at the Centre for Pharmaceutical Engineering Science to the Aesica Innovation Board and builds upon the relationship established in 2009 between both parties.
The Centre offers a number of processing technologies including hot melt extrusion, but relies on the GMP expertise of the formulation development team at Aesica to manufacture GMP clinical trial supplies.
Speaking of the partnership, Paul Titley, managing director, Formulation Development, Aesica says: “We provide GMP contract manufacturing services to six other universities, but this partnership is particularly important and unique as it is mutually beneficial. While the team at Bradford has development expertise in several key approaches and as such can evaluate the viability of compounds presented by virtual and small pharma organizations, our GMP expertise is crucial to take the compounds into clinical trials, which is vital. By working with such organizations at an early stage we would hope to cement long term development and manufacturing partnerships and expedite the leap from concept to commercialization with a clear and proven route to market. In addition, the facilities at the Centre for Pharmaceutical Engineering Science will enable us to further enhance our overall formulation development service offering which will add value to our existing clients.”
Dr. Shukla adds: “Aesica is a well established pharmaceutical company with exemplary GMP credentials, which we were keen to tap into for the benefit of our contacts within the multinational pharma community. Our facilities at the Centre are second to none and we believe this coupled with our research expertise will deliver significant benefits to Aesica as the partnership evolves.”
The partnership follows a sustained period of expansion by Aesica, which has seen the CMO double its workforce and establish three manufacturing sites in Europe and drive forward plans to expand its offer across America.
In addition, Aesica has recently announced plans to create up to 100 new jobs at its Queenborough, UK, facility between now and 2015 as the site prepares for significant expansion.
Furthermore, the company was recently ranked in The Sunday Times HSBC International Track 200, a newly created list that ranks Britain’s private companies with the fastest growing international sales.
Published in July, the table listed Aesica as the second best performing company in the North East of England after its international sales grew by 37 per cent over the course of the two years to December 2011 - international sales now represent 98 per cent of the company’s overall turnover.
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018